BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16611093)

  • 1. Novel treatments of schizophrenia: targeting the neurotensin system.
    Kinkead B; Nemeroff CB
    CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):205-18. PubMed ID: 16611093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotensin agonists as an alternative to antipsychotics.
    Boules M; Fredrickson P; Richelson E
    Expert Opin Investig Drugs; 2005 Apr; 14(4):359-69. PubMed ID: 15882113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs.
    Binder EB; Kinkead B; Owens MJ; Nemeroff CB
    Biol Psychiatry; 2001 Dec; 50(11):856-72. PubMed ID: 11743941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?
    Cáceda R; Kinkead B; Nemeroff CB
    Semin Clin Neuropsychiatry; 2003 Apr; 8(2):94-108. PubMed ID: 12728409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating.
    Binder EB; Kinkead B; Owens MJ; Kilts CD; Nemeroff CB
    J Neurosci; 2001 Jan; 21(2):601-8. PubMed ID: 11160439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotensin, schizophrenia, and antipsychotic drug action.
    Kinkead B; Nemeroff CB
    Int Rev Neurobiol; 2004; 59():327-49. PubMed ID: 15006494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotensin receptor agonists and antagonists for schizophrenia.
    Richelson E; Fredrickson PA; Boules MM
    Am J Psychiatry; 2005 Mar; 162(3):633-4; author reply 635. PubMed ID: 15741499
    [No Abstract]   [Full Text] [Related]  

  • 8. The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.
    Feifel D; Mexal S; Melendez G; Liu PY; Goldenberg JR; Shilling PD
    Neuropsychopharmacology; 2009 Jul; 34(8):2011-8. PubMed ID: 19322170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice.
    Mechanic JA; Sutton JE; Berson AE; Wu X; Kwan J; Schreiber R; Pang Z; Button DC
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):466-75. PubMed ID: 19223157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotensin agonists: potential in the treatment of schizophrenia.
    Boules M; Shaw A; Fredrickson P; Richelson E
    CNS Drugs; 2007; 21(1):13-23. PubMed ID: 17190526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotensin receptor agonists and antagonists for schizophrenia.
    Robertson VB; Wilson MS
    Am J Psychiatry; 2005 Mar; 162(3):634; author reply 635. PubMed ID: 15741502
    [No Abstract]   [Full Text] [Related]  

  • 12. Does neurotensin mediate the effects of antipsychotic drugs?
    Kinkead B; Binder EB; Nemeroff CB
    Biol Psychiatry; 1999 Aug; 46(3):340-51. PubMed ID: 10435199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioactive analogs of neurotensin: focus on CNS effects.
    Boules M; Fredrickson P; Richelson E
    Peptides; 2006 Oct; 27(10):2523-33. PubMed ID: 16882457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotensin agonists: possible drugs for treatment of psychostimulant abuse.
    Richelson E; Boules M; Fredrickson P
    Life Sci; 2003 Jun; 73(6):679-90. PubMed ID: 12801589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotensin-dopamine interactions: relevance to schizophrenia and the action of antipsychotic drugs.
    Stowe ZN; Bissette G; Nemeroff CB
    Yakubutsu Seishin Kodo; 1991 Feb; 11(1):49-59. PubMed ID: 1679273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic, but not acute, dosing of antipsychotic drugs alters neurotensin binding in rat brain regions.
    Holtom PE; Needham PL; Bennett GW; Aspley S
    Br J Pharmacol; 2000 Nov; 131(5):990-6. PubMed ID: 11053221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance.
    Feifel D; Melendez G; Murray RJ; Tina Tran DN; Rullan MA; Shilling PD
    Psychopharmacology (Berl); 2008 Oct; 200(2):197-203. PubMed ID: 18568338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic drug-like facilitation of latent inhibition by a brain-penetrating neurotensin-1 receptor agonist.
    Feifel D; Shilling PD; Fazlinejad AA; Melendez G
    J Psychopharmacol; 2016 Mar; 30(3):312-7. PubMed ID: 26783230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotensin: A role in substance use disorder?
    Ferraro L; Tiozzo Fasiolo L; Beggiato S; Borelli AC; Pomierny-Chamiolo L; Frankowska M; Antonelli T; Tomasini MC; Fuxe K; Filip M
    J Psychopharmacol; 2016 Feb; 30(2):112-27. PubMed ID: 26755548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain.
    Kinkead B; Shahid S; Owens MJ; Nemeroff CB
    J Pharmacol Exp Ther; 2000 Oct; 295(1):67-73. PubMed ID: 10991962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.